Cost-effectiveness of lenvatinib plus pembrolizumab versus chemotherapy for recurrent mismatch repair-proficient endometrial cancer after platinum-based therapy
- Resource Type
- Article
- Source
- In
Gynecologic Oncology March 2024 182:70-74 - Subject
- Language
- ISSN
- 0090-8258